dehaze raises €3.2M for AI chronic disease detection

dehaze, a Munich-based healthtech AI company, has raised €3.2 million in a seed funding round led by YZR Capital and DN Capital, with participation from Angel Invest, Zoho, and Better Ventures. The funding will support the company’s efforts to develop a foundational AI model for chronic disease detection.

dehaze’s platform uses causal AI to analyse large volumes of patient data, enabling healthcare payers to identify individuals at risk of chronic conditions earlier, improve intervention outcomes, and reduce costs.

Chronic diseases remain the largest cost driver in global healthcare systems, accounting for around 70 per cent of deaths and more than $8 trillion in annual spending, according to the World Health Organization. Despite the abundance of available health data, clinicians typically review only a small fraction before making decisions, contributing to a significant share of conditions going undetected at earlier, more treatable stages.

dehaze aims to address this gap through a purpose-built model designed specifically for healthcare data. Its system processes heterogeneous datasets at scale and provides causal insights that support decision-making for both clinicians and insurers. The company says its approach can help reduce medical loss ratios while enabling earlier and more effective treatment.

Marius Klages, co-founder and CEO of dehaze, said the company was built in Munich from the ground up as a foundational AI model for chronic disease detection, rather than as a chatbot or dashboard-style solution:

Our customers are global from day one, because the problem is global from day one. The speed at which payers are signing with us confirms what we believed when we started: this is a category that will be defined over the next few years, and dehaze is going to define it.

The new funding will be used to expand both the technical and commercial teams and to further develop platform capabilities, including features for recommending next-best actions and improving traceability.